Send us a text

Summary:  A new option is coming for an often-underreported condition:  postpartum depression.  The FDA Fast Tracked the review of Zurzuvae, thereby acknowledging that this new drug may fill an unmet medical need.  We discuss how this drug works, how quickly it can have an effect, and (as usual) the importance of actively participating in the risk-benefit discussion and subsequent monitoring with your healthcare professional.

 Topics:

·      Fast-Tracked 01:05

·      Incidence of Postpartum Depression 06:00

·      Postpartum Depression 07:10

·      Previous Drug Options 08:00

·      Zulresso IV 08:30

·      Cost/Insurance? 09:00

·      Causes of Depression 09:30

·      Zurzuvae Mechanism of Action 10:30

·      Neuroactive Steroid 11:00

·      Zurzuvae Dosing 12:00

·      How Soon to See Effect 12:30

·      Zurzuvae for Major Depression? 13:45

·      Side Effects 14:30

·      988 15:15

·      Breastfeeding 15:30

·      Risk-Benefit 15:45

·      Phases of Clinical Research 17:00

·      Phase 4 of Clinical Research – Post Marketing 18:00

·      Drug Journaling 18:45

·      Drug-Drug Interactions 19:45

·      Monitor and Participate 24:45

Questions and comments to [email protected]